Clinical Trial Update: A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

This item reports the completion of a Phase I/II safety trial of DE-120 Injectable Solution for age-related macular degeneration conducted by Santen Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• DE-120 Injectable Solution (DE-120)

Snippet

Sponsor: Santen Inc. | Conditions: Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED